Pharmaco - Articles
Breast cancer is one of the most prevalent tumor types, with a little over 200,000 cases expected to be diagnosed in the this year. Mortality rates declined by 2.3% between 1990 and 2000 due to improvements in diagnosis and treatment and 5-year survival rates now stand at 97% for localized tumors,…
----Endovascular intervention, employing minimally invasive, catheter-based technologies, is expected to become the dominant therapeutic modality for atherosclerotic diseases in the lower limbs, according to a new report published by THE SAGE GROUP (click here for the report). "Already the preferred initial interventional therapy for most types of lesions in aortoiliac disease, endovascular intervention is rapidly becoming the initial therapy for many types of femoropopliteal disease," stated Mary L. Yost, President of THE S…
About 700,000 Americans suffer a new or recurrent stroke each year usually due to atherosclerosis in the carotid/vertebral arteries. Recovery from stroke is unpredictable and rarely complete and consequently 15-30% of ischemic stroke victims are permanently disabled and 20% require prolonged institu…
Approximately 9% of the population suffers from moderate to severe non-cancer-related pain, a figure that includes 40-70 million individuals with chronic pain. This condition precipitates other serious pathologies such as depression and is associated with an estimated pharmaceuticals market of US$1…
Since the first successful kidney transplantation more than 40 years ago, the treatment of end-stage organ failure has dramatically improved. Many organs are now transplanted, the most common of which include (procedures performed in the in 2001) the kidney (14,000), heart (2,000), liver (5,000) and l…
The aging population will contribute to an expansion of the already massive Alzheimer's disease therapy market. The number of sufferers is expected to grow from 16 million patients to 21 million by 2010 in the seven major pharmaceutical markets driving sales in these regions worth $4.7 billion…
Steve Westcott MD Melbourn Scientific provides some pragmatic advice Any method must be capable of providing results that have integrity and are fit for purpose. Validation is a crucial way of ensuring that challenges such as a change of operator or small changes in analytical conditions will still result in reliable data. However, although the validation protocol states the challenges that are to be applied to the analytical process and the deviations from the norm that are considered acceptable,…
Pharma companies have been making the headlines for all the wrong reasons recently. Reports in the press suggest that AstraZeneca will likely be found guilty by the EC of competition abuses following the charge in July 2003 of allegedly "misusing the patent system and other regulatory procedures for the marketing of drugs". AstraZeneca could face fines that reach as much as 10% of turnover. Eli Lilly is also in the spotlight for marketing abuses, being issued a subpoena over the marketing and promotional prac…
Self-Confidence or No Confidence? Having worked with young adults in a supportive role, assisting them to get their foot on the career ladder, it has become evident that generally speaking the one thing they have in common is a lack of confidence. At the other end of the scale, in my role as a sales manager I have come across some extremely confident – in some cases, even arrogant – candidates. Neither of these situations is ideal. In order for a prospective employer to hire you, they have to believe that you will be competent in…
The aging population will contribute to an expansion of the already $30 billion neurodegenerative market. The market for Alzheimer's disease therapy is expected to grow from 16 million patients to 21 million by 2010 in the seven major pharmaceutical markets and represents a major component of this market. Alzheimer's disease drives sales in these regions worth $4.7 billion, a figure set to increase to $6.1 billion by the year 2005 and $ 7.8 billion by the year 2010 (for a full analysis of this field click here or here). …
DailyUpdates 17th August, 2004: Researchers from Protein Design Laboratories report that an antibody-drug conjugate that links the chemotherapeutic agent Auristatin to a prostate cancer specific antibody, anti-TMEFF2 mAb, via a cathepsin B-sensitive linker prevents tumor growth in a murine model of prostate cancer. Prostate cancer is one of the most common forms of solid tumors with 230,000 new cases expected to be identified this year in the alone. Prognosis is often goo…
R112 is an intranasal inhibitor to SYK, or spleen tyrosine kinase, which is a novel drug target for respiratory diseases such as allergic rhinitis and asthma. SYK is involved in immunoglobulin E signaling in mast cells, which play important roles in both early and late phase allergic reactions. R112 is the most advanced compound in development with this mechanism of action for allergic rhinitis: a multidose safety trial of 24 patients conducted in 2003 indicated that R112 has a favorab…
and have generated about $545,000 in sales in the first five months of their state-sponsored websites offering Canadian drugs, according to figures made public last week. These are the first public accounting figures showing how much residents are using the websites, which were created by the governors of the two states. Yet the level of sales recorded represents a fraction of the cross-border bus…
DailyUpdates 11th August: Lipoxin A4 (LXA4) mimics shown reduce inflammation by inhibiting the p38-MAPK pathway-further proof of concept for LXA4 analogues in preclinical development The p38-MAPK pathway has long been targeted by the pharmaceutical industry in an attempt to identify new…
Although skin and skin structure infections represent one of the most common types of bacterial ailments, they are still relatively infrequent when compared to respiratory tract and urinary tract infections. Skin and skin structure infections accounted for only 3% of the $6.5 billion US drugstore sales attributable to antibacterial infections in 2003. However, skin infections are the one sector of the anti-bacterial market wher…
Datamonitor estimates that there are 127 million obese people in the , , , , , and the and over half of them reside in the . Despite increasing health awareness campaigns and attempts to slow down the startling increase in obesity rates, Datamonitor predicts that the prevalence of obesity will increase to 168 million in the alone by 2012. Health complications and comorbidities associated with obesity are a huge drain on national heal…
However, its administration by subcutaneous injection is precluding therapy in up to 80% of patients. Datamonitor's Laura Harris looks at some later line therapies that could be orally available, prompting greater uptake... Fuzeon (enfuvirtide) was developed by Roche and Trimeris and launched in the in March 2003, with European launches taking place throughout 2003 and 2004. It was licensed as a salvage therapy in patients who have demonstrated virologic failure to alternative antiretroviral (ARV) treatment and have developed resistant strains of HIV. Fuzeon is the first novel HIV drug to reach the market for…
What is a CV? A CV in its purest form is nothing more and nothing less than a chance to market yourself to prospective recruiters and employers to increase your chances of being invited to an interview. A CV is an Interview-Winning Tool. It is not a Personal Biography, or a List of your skills and experience, it is a fluid document which means different things to different people, but is relevant to all. CV Myths Before looking at what makes a good CV, lets first dispel a few myths: ‘The more they know about me, the more chance they have of being impressed’ Wrong…
DailyUpdates 13th July: Acute pain resulting from conditions such as headache, muscle spasms, dental problems or following surgery, affects 90 million Americans every year. A recent study has demonstrated the analgesic activity of corticotropin-releasing-hormone (CRH) and has shown that this activity is probably due to activity within the central nervous system. It has been estimated that 9% of the population suffers from moderate to severe n…
Less than one third of hypertensive adults with dyslipidemia are drug-treated, according to findings from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. In addition, the research also showed that fewer than half of those treated achieve recommended lipid levels. This suggests a need for a more aggressive treatment of dyslipidemic hypertensives and highlights the potential of cross risk-factor single-pill combination…